Thomas Bachelot

1994–2025 年に発表

別表記
Thomas BACHELOT
138
論文数
26,129
被引用数
79
h 指数
128
i10 指数

被引用数

Thomas Bachelot の年別被引用数1964 年: 被引用 1 件1993 年: 被引用 6 件1995 年: 被引用 1 件1996 年: 被引用 2 件1998 年: 被引用 2 件1999 年: 被引用 3 件2000 年: 被引用 10 件2001 年: 被引用 15 件2002 年: 被引用 10 件2003 年: 被引用 9 件2004 年: 被引用 11 件2005 年: 被引用 12 件2006 年: 被引用 20 件2007 年: 被引用 20 件2008 年: 被引用 24 件2009 年: 被引用 43 件2010 年: 被引用 50 件2011 年: 被引用 74 件2012 年: 被引用 149 件2013 年: 被引用 227 件2014 年: 被引用 196 件2015 年: 被引用 219 件2016 年: 被引用 217 件2017 年: 被引用 221 件2018 年: 被引用 267 件2019 年: 被引用 860 件2020 年: 被引用 1,104 件2021 年: 被引用 1,196 件2022 年: 被引用 979 件2023 年: 被引用 875 件2024 年: 被引用 1,392 件2025 年: 被引用 799 件2026 年: 被引用 27 件1965〜1992 年は被引用が無いため表示していません1994 年は被引用が無いため表示していません1997 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,840 件、この内訳の 21.8%中国: 引用元論文 1,277 件、この内訳の 9.8%イタリア: 引用元論文 914 件、この内訳の 7%フランス: 引用元論文 880 件、この内訳の 6.8%イギリス: 引用元論文 671 件、この内訳の 5.2%ドイツ: 引用元論文 628 件、この内訳の 4.8%スペイン: 引用元論文 542 件、この内訳の 4.2%カナダ: 引用元論文 433 件、この内訳の 3.3%ベルギー: 引用元論文 378 件、この内訳の 2.9%スイス: 引用元論文 375 件、この内訳の 2.9%日本: 引用元論文 352 件、この内訳の 2.7%オランダ: 引用元論文 328 件、この内訳の 2.5%
0%21.8%その他 26.1%

分野

  • Medicine60.8%
  • Biochemistry, Genetics and Molecular Biology27.3%
  • Immunology and Microbiology7.8%
  • Neuroscience1.3%
  • Computer Science0.8%
  • Engineering0.5%
  • その他1.5%

トピック

  • Advanced Breast Cancer Therapies8%
  • HER2/EGFR in Cancer Research6.5%
  • Breast Cancer Treatment Studies4.9%
  • Cancer Immunotherapy and Biomarkers4.5%
  • Cancer Genomics and Diagnostics3.9%
  • Immunotherapy and Immune Responses2.8%
  • その他69.4%

共著者

全論文

検索で開く
  1. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joseph A. Sparano, Tanja Španić, Sandra M. Swain, Sergei Tjulandin, Masakazu Toi, Dario Trapani, Andrew Tutt, B. Xu, Giuseppe Curigliano, Nadia Harbeck - Annals of Oncology 2023 被引用: 844

  2. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patricia Kannouche, Virginie Marty, Magali Lacroix‐Triki, Véronique Dièras, Fabrice André - Nature Medicine 2023 被引用: 370

  3. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 被引用: 2,009

  4. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2011 被引用: 2,828

  5. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Céline Callens, Jérôme Lemonnier, Frédérique Berger, Suzette Delaloge, François‐Clément Bidard, Barbara Pistilli, Florence Dalenc, Barbara PISTILLI, Florence DALENC, Thomas BACHELOT, Coraline Dubot, Jean‐Sébastien Frenel, Jean-­Marc Ferrero, Sylvain Ladoire, Jean-Marc FERRERO, Marie‐Ange Mouret‐Reynier, Anne‐Claire Hardy‐Bessard, Alain Lortholary, Anne-Claire HARDY-BESSARD, Camille Chakiba, Laëtitia Stefani, P Soulié, Jean-Philippe Jacquin, Jérôme Edouard Plaza, Florian Clatot, Luís Teixeira, Florian CLATOT, Luis TEIXEIRA, Olfa Derbel, Claire Garnier Tixidre, Catherine Delbaldo, Lionel MOREAU, Caroline Cheneau, Jean-François Paitel, Chantal BERNARD-MARTY, Dominique Spaëth, Dominique Genet, Isabelle MOULLET, Nathalie BONICHON-LAMICHHANE, Laura DEIANA, Charlotte GREILSAMER, Laurence Venat‐Bouvet, Valérie Delecroix, Adrien MELIS, Hubert Orfeuvre, Suzanne Nguyen, Éric Legouffe, Alain Zannetti, Romuald Le Scodan, Nadine Dohollou, Philippe DALIVOUST, Olivier Arsène, Nathalie MARQUES, Thierry Petit, Delphine MOLLON, Jérôme Dauba, Nathalie Bonnin, François MORVAN, Miriam Gardner, Adina MARTI, Charles-Briac Levaché, Emma Lachaier, Mihaela ACHILLE, Christophe VALMAR, Ryan Bouaita, Jacques Médioni, Cyril Foa, Chantal BERNARD-MARTY, Francesco Del Piano, Michel GOZY ほか 19 名 - The Lancet Oncology 2022 被引用: 317

  6. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours

    著者: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 579

  7. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 349

  8. Genomic characterization of metastatic breast cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2019 被引用: 750

  9. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 549

  10. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2022 被引用: 197

  11. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier - The Lancet Oncology 2019 被引用: 477

  12. Genomics to select treatment for patients with metastatic breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amélie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Gonçalvès, Thomas Bachelot, Ivan Bièche - Nature 2022 被引用: 168

  13. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 320

  14. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

    著者: , , , , , , , , , , , , , , , , , - Cancer Research 2009 被引用: 744

  15. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    著者: , , , , , , , , , , , , , , , , , - Cancer Research 2009 被引用: 797

  16. Treatment strategies for breast cancer brain metastases

    著者: , , - British Journal of Cancer 2020 被引用: 238

  17. Efficacy of PI3K inhibitors in advanced breast cancer

    著者: , , , , - Annals of Oncology 2019 被引用: 217

  18. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

    著者: , , , , , , , , , , , , , , , - The Lancet Oncology 2012 被引用: 742

  19. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sandra Anabel Ostoich, Hans Wildiers, Kevin Punie, Joëlle Collignon, Guy Jérusalem, Andrea Gombos, Giuliano Borges, Pedro Emanuel Rubini Liedke, Marcelle Goldner Cesca, Patrícia Medeiros Milhomem Beato, Laura Testa, Hélio Pinczowski, Liane Rapatoni, Debora de Melo Gagliato Jardim, José Bines, David W. Cescon, Jamil Asselah, Andre Blais, Joanne Yu, Jennifer Friedmann, Cristiano Ferrario, Binghe Xu, Shusen Wang, Qingyuan Zhang, ZeFei Jiang, Zhongsheng Tong, Quchang Ouyang, Jingfen Wang, Tingjing Yao, Yongsheng Wang, Xiaojia Wang, Meili Sun, Hui Li, Shu Wang, Yuan Sheng, Aimin Zang, Zhang Zhanmin, Wenyan Chen, Xian Wang, Zhong Ouyang, Wěi Li, Barbara Pistilli, Thomas Bachelot, Mony Ung, Cristian Villanueva, Delphine Garbay, Anne-Claire Hardy-Bessard, Audrey Mailliez, Stéphanie Bécourt, William Mina, Thomas Decker, Julia Radosa, Andreas Schneeweiß, Michael Braun, Bahriye Aktas, Gábor Rubovszky, Zsuzsanna Pápai, Tibor Csőszi, Yousuf Al-Farhat, Ankit Patel, Vineet Govinda Gupta, Richu Sharma, Chandrakanth Mosale Venkatesha, Shailesh Bondarde, Somnath Roy, Nikhil Ghadyalpatil, Lalit Sen Sharma, Rajani Priya Yedla, Michelino De Laurentiis, Ida Paris ほか 101 名 - Journal of Clinical Oncology 2024 被引用: 140

  20. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

    著者: , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 198

  21. Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2020 被引用: 178

  22. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ingrid Garberis, Fabrice André - Nature Medicine 2021 被引用: 158

  23. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

    著者: , , , , , , , , , , , , , , , , , , , - Nature Medicine 2024 被引用: 128

  24. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar, on behalf of the SOPHIA Study Group - Journal of Clinical Oncology 2022 被引用: 80